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Abstract : This study aimed to evaluate the frequency, distribution, and cor-
responding histology of MUC1 expression in colorectal cancer and examine its 
association with clinicopathological factors.  MUC1 expression was conrmed 
in 86 of 169 surgically resected colorectal cancers （51%）, although the ratio 
of MUC1-positive cells was less than 5% in 33 cases （20%）, 5-50% in 46 
cases （27%）, and greater than 50% in only 7 cases （4%）.  None or less 
than 5% of MUC1 expression cases were classied as L-group cancers （116 
cases, 69%）, while cancers showing higher than 5% expression were classied 
into the H-group （53 cases, 31%）.  Analysis of the intratumoral distribution 
of positive cells in the H-group cases showed MUC1 expression distributed 
predominantly in the upper layers in 3 cases （6%）, in the lower layers in 
18 cases （34%）, and in all layers in 32 cases （60%）.  MUC1 expression was 
observed in various histomorphological cancer forms, but the most frequent 
expression was noted in the monolayer cuboidal （pancreatobiliary-type） 
neoplastic glands.  Considering the relationship between MUC1 expression 
and clinicopathological factors, H-group cases demonstrated signicantly larger 
lesions showing a greater number of ulcerated-type cancers, deeper invasion, 
poorer differentiation, higher frequency of budding, and higher rate of lymph 
node metastasis than L-group cancers.  Furthermore, there was a difference 
of 10% between the H-group and L-group with regard to the frequency of 
relapse/tumor mortality three years after surgery.  In colorectal cancer, MUC1 
expression increases with progression of the tumor indicating that it is one of 
the useful indicators of malignancy and may facilitate appropriate treatment 
regimens ; however, as its expression is heterogeneous and localized, it will be 
necessary to conrm the state of MUC1 expression by case.
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Introduction
　Up to the early 1990s, there was an increase in the rate of colorectal cancer in Japan that 
coincided with the westernization of eating habits and increased prevalence of overweight 
and obese individuals Thereafter, the rate began to level off and presently, approximately 
105,000 people are diagnosed with colorectal cancer every year.  In recent years, advance-
ments in medical care and diagnostic technologies have resultsed in colorectal cancers being 
detected at an early stage, and improved surgical or endoscopic resection has increased the 
number of cases with complete cure.  However, the number of deaths still exceeds 40,000 
people each year 1）.
　In accordance with the progression of colorectal cancers, chemotherapy is frequently used 
as an adjuvant treatment or as part of multidisciplinary therapy 2）.  Although the effective-
ness of chemotherapy has improved over the years, results remain unsatisfactory 3）.  Further 
improving the cure rates of cancer chemotherapy will require that the treatment regimen 
and drugs used to be carefully selected according to the specic traits of tumor cells, such 
as their sensitivity to specic anticancer drugs and the presence of tumor-associated antigens. 
This importance of personalized treatment will also be considered in the treatment of 
colorectal cancer, because some colorectal cancers show a heterogeneous cell lineage and 
partially or predominantly lack the characteristics of an intestinal-type cancer.
　MUC1 is a mucin antigen highly expressed in pancreatobiliary-type cancer, such as ductal 
adenocarcinoma of the pancreas or bile duct, and is a marker of heterogeneity in colorectal 
cancer.  We recently decided to investigate MUC1 expression in colorectal cancer because it 
is a marker for poor prognosis 4）, its expression may affect the selection of chemotherapeutic 
agents and use of MUC1-cytotoxic T-lymphocyte （CTL） immunotherapy 5）, and little is 
reported about MUC1 expression in colorectal cancer tissues to date 6，7）.
　This study investigated the frequency and distribution of MUC1 expression in colorectal 
cancer with respect to the corresponding histology, and examined the association of these 
ndings with the patient’s pathological prognostic factors.
Materials and Methods
Objectives
　The study comprised 169 of 203 cases of surgical resection conducted from 2006 to 2007 
at the authors’ respective facilities and histologically diagnosed as colorectal adenocarcinoma 
（excluding cases of serous membrane-invasive cancers and directly invasive cancers to other 
organs）.  The patients’ average age was 71.2 years （36-92 years）, with a male : female ratio 
of 1 : 0.6.  The average tumor diameter was 43.7 mm, with tumor localized in the cecum 
in 19 cases, in the colon in 100, and in the rectum in 50.  Based on the invasion depth 
（T classication 8））, 21 cases were classied as T1, 35 as T2, and 113 as T3.  Lymph node 
metastases were noted in 51 cases.  Seventy-four cases were being treated with adjuvant 
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chemotherapy （5 cases were unconrmed）.  Furthermore, outpatient clinical records of 129 
patients for three years after surgery were examined to assess post-operative prognosis.
Immunohistochemistry
　MUC1 expression was examined immunohistochemically.  The staining was performed 
using the BENCHMARK （Ventana Medical Systems, Inc.  Tucson, AZ, USA） automated 
avidin-biotin complex detection immunostaining system.  In each case, 3-μm, ultrathin 
sections were cut from 1-2 formalin-xed parafn-embedded tissue blocks for immunostain-
ing.  These slices were stained with anti-MUC1 monoclonal antibody （Ma695, Novocastra, 
Newcastle upon Tyne, UK ; diluted 1 : 100） and subsequently observed under an optical 
microscope.  For each section, the ratio of MUC1-positive cells to tumor cells was calculated. 
Two types of positive reactions were observed in the tumor cells.  The rst was a thick, 
outer-layer staining of the tumor cell membranes, while the second was a light, occasion-
ally dense, diffuse, granular staining of the cytoplasm.  As the latter positive reaction was 
observed in the normal epithelium, only the former positive reaction was considered signi-
cant for MUC1 detection.
Clinicopathological examination
　We rst examined the frequency and distribution of MUC1 expression in the cancer tis-
sue, and then compared these with MUC1 expression in lymph node metastatic lesions from 
the study patients, 59 pancreatic cancers, and 10 small intestinal cancers.  Next, histomorpho-
logical features showing MUC1 expression were evaluated.  Finally, the relationship between 
MUC1 expression and clinicopathological factors, especially those related to unfavorable 
prognosis, was investigated.  For statistical analysis, chi-square tests and Student’s t-tests were 
used, and a P-value＜ 0.05 was considered signicant.
Results
Frequency and distribution
　MUC1 expression was conrmed in 86 cases （51%）; however, the proportion of MUC1-
positive cells was 0% in 83 of the tumor samples （49%）, 1-5% in 33 cases （20%）, 5-50% 
in 46 cases （27%）, and greater than 50% in only 7 cases （4%）.  Hence, the negative and 
extremely low （＜ 5%） MUC1-expressing cases （hereafter known as the MUC1 L-group） 
comprised approximately 70% of the total number of cases （Table 1）.  In the other 53 
cases with higher MUC1 expression （＞ 5% of tumor cells, hereafter known as the MUC1 
H-group）, we analyzed the intratumoral distribution of MUC1 expression and found that 3 
cases （6%） showed expression predominantly in the upper layers, 18 cases （34%） in the 
lower layers, and 32 cases （60%） in all layers （Table 2）.  Based on the invasion depth （T 
classication）, only 1 of 21 T1 cancer cases （5%）, 11 of 35 T2 cancer cases （31%）, and 
41 of 113 T3 cancer cases （36%） were from the MUC1 H-group （Table 3）.  Of the 51 
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cases of lymph node metastases, 18 of 22 cases （82% ; 3 cases untested） in the H-group 
continuously exhibited high MUC1 expression （＞ 5%）, while in the L-group, 10 of 26 cases 
（38%） revealed high MUC1 expression.  In the comparison of colorectal cancers with pan-
creatic or small intestinal cancers, we found that 7 of 169 colorectal cancers （4%） showed a 
MUC1-positive cell ratio of ＞ 50%, compared to 41 of 59 pancreatic cancers （70%） and 3 
of 10 small intestinal cancer （30%） （Table 4）.
Table 1.  Frequency of MUC1 expression in colorectal cancer （n=169） 
MUC1
expression
n（%） Ratio of MUC1
positive cells
n（%） Grouping n（%）
Negative 83（49%） 0% 83（49%）
MUC1 L-group 116（69%）
Positive 86（51%）
＜ 5% 33（20%）
5-50% 46（27%）
MUC1 H-group  53（31%）
50% ≤  7（ 4%）
Table 2.  Distribution of MUC1 positive cells in 
colorectal cancer （MUC1 H-group） （n=53）
Distribution n（%）
Upper layer  3（ 6%）
Upper and lower layers 32（60%）
Lower layer 18（34%）
Table 3.  Relation between invasion depth （T stage） and 
MUC1 expression
MUC1 H-group
（n=53）
MUC1 L-group
（n=116）
T1 （n=21）  1/21 （ 5%） 20/21 （95%）
T2 （n=35） 11/35 （31%） 24/35 （69%）
T3 （n=113） 41/113（36%） 72/113（64%）
Table 4.  Comparison of MUC1 expression among colorectal, small intestinal and 
pancreatic cancer
Colorectal cancer
（n=169）
Small intestinal cancer
（n=10）
Pancreatic cancer
（n=59）
Frequency
（MUC1 positive cell
ratio of ＞ 50%）
7（ 4%） 3（30%） 41（70%）
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MUC1 expression and histological morphology
　MUC1 expression was observed in various histological types of colorectal cancer, such 
as in cancer cells showing cribriform structure, small or budding cancer cell nests, invasive 
micropapillary carcinoma components, mucinous carcinoma components, or scirrhous tubular 
adenocarcinoma components （similar to pancreatic cancer）.  In particular, we noticed fre-
quent expression of MUC1 in the monolayer, cuboidal neoplastic glands （pancreatobiliary-
type adenocarcinoma） transformed from columnar neoplastic glands with pseudostratified 
spindle-shaped nuclei and densely colored cytoplasm （intestinal-type adenocarcinoma） （Fig. 
1）.  MUC1 expression in common intestinal-type tubular adenocarcinomas was also noticed, 
although it was infrequent.
MUC1 expression and clinicopathological factors
　We compared the clinicopathological factors in 53 cases （31%） of the MUC1 H-group 
with those in 116 cases （69%） of the MUC1 L-group （Table 5）.  No signicant differ-
ence was observed in age, gender, or tumor localization between the groups ; however, the 
MUC1 H-group exhibited signicantly greater tumor size than the MUC1 L-group （5.2 cm 
vs. 4.0 cm diameter, respectively）, more ulcerated-type tumors （91% vs. 76%, respectively）, 
deeper inltration depth for T2 and T3 cancer cases （98% vs. 83%, respectively）, lower 
differentiation state （moderately to poorly differentiated : 74% vs. 57%, respectively）, greater 
frequency of budding （58% vs. 41%, respectively）, and higher rate of lymph node metastasis 
Fig. 1.  Histological and MUC1 immunostaining of colorectal cancer.
Note the monolayer cuboidal neoplastic glands （pancreatobiliary-type adenocar-
cinoma） （△） transformed from columnar neoplastic glands with pseudostrati-
fied spindle-shaped nuclei （intestinal-type adenocarcinoma） （○）. MUC1 
expression is seen only in the pancreatobiliary type glands （×）.
Takahiro HOBO, et al204
（43% vs. 21%, respectively）.  These ndings indicated a strong correlation between MUC1 
expression and malignancy factors.  Furthermore, a difference of 10% in the frequency of 
relapse/tumor mortality between the H-group （35%） and the L-group （25%） was observed 
three years after surgery.  In an examination of only T3 cancer cases, several factors failed 
to show statistically significant differences, but there remained a significant difference in 
lymph node metastasis between the H-group （47%） and the L-group （27%） （Table 6）. 
Adjuvant chemotherapy was administered almost equally to patients in both groups, namely 
26 cases in the MUC1 H-group （51%, 2 cases unknown） and 48 cases in the MUC1 
L-group （42%, 3 cases unknown）.
Discussion
　The histological structure of colorectal cancers is fairly uniform, with the majority show-
ing intestinal-type tubular adenocarcinomas with high expression of the intestinal markers 
CDX2 9） and MUC2 10）.  On the other hand, the MUC1 examined in this study is con-
Table 5.  MUC1 expression and clinicopathological factors
MUC1 H-group MUC1 L-group P-value
n 53 116 -
Age （years） 73（36-92） 70（39-92） NS
Gender （male : female） 37：16 68：48 NS
Tumor size （cm） 5.2（1.7-14） 4.0（0.9-9） 0.001
Protuberant type vs. ulcerated type （%）  9% vs. 91% 24% vs. 76% 0.03
Localization, left side colon vs. right side colon （%） 68% vs. 32% 66% vs. 34% NS
Invasion depth, T1 vs. T2＋ T3 （%）  2% vs. 98% 17% vs. 83% 0.005
Differentiation, tub1 vs. tub2-por （%） 26% vs. 74% 43% vs. 57% 0.04
High budding （%） 58% 41% 0.03
Lymph node metastasis （%） 43% 21% 0.005
Recurrence/tumor mortality at 3 years post-operation （%） 35% 25% NS
NS ; not signicant
Table 6.  MUC1 expression and clinicopathological factors in T3 cancers
MUC1 H-group MUC1 L-group P-value
n 41 72 -
Tumor size （cm） 5.8（2.5-14） 4.8（10-90） 0.01
Protuberant type vs. ulcerated type （%）  5% vs. 95% 10% vs. 90% NS
Differentiation, tub1 vs. tub2-por（n） 20% vs. 80% 33% vs. 67% NS
High budding （%） 59% 50% NS
Lymph node metastasis （%） 47% 27% 0.03
Recurrence/tumor mortality at 3 years post-operation （%） 42% 35% NS
NS ; not significant
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sidered a pancreatobiliary marker and is commonly expressed in normal pancreatobiliary 
epithelium cells and pancreatobiliary-type adenocarcinoma.  Therefore, when an unknown 
hepatic tumor is encountered, coimmunostaining of CDX2, MUC2, and MUC1 would be 
useful to distinguish between colorectal and pancreatobiliary cancers 11）.  However, MUC1 
expression has been reported at various frequencies （32-50% 4，12）） in colorectal cancer 13）. 
The reasons for the difference in positivity rates may include differences in the MUC1 
antibody used, the signicant positive reactions graded, and in standards for classifying posi-
tive cases.  In considering all levels of MUC1 expression, our study found MUC1 expression 
in approximately half of the cases.  However, only 4% of these （7 of 169 cases） showed a 
MUC1-positive cell ratio of greater than 50%.  This result was in contrast with 70% （41 of 
59 cases） of pancreatic cancers which exhibited MUC1 positivity at a ratio of greater than 
50% in additional studies.  Thus, unlike for pancreatobiliary cancers, MUC1 expression in 
colorectal cancer can only be considered a secondary trait.
　However, even if MUC1 expression in colorectal cancer is a minor phenomenon, its 
expression should not be overlooked.  In this study, MUC1 expression was clearly observed 
in 53 cases classied into the MUC1 H-group, of which all except one were either T2 or T3 
advanced cancer cases.  Therefore, the frequency of MUC1 expression tended to be higher 
with the stage of the tumor, consistent with a previous study 14）.  Furthermore, the MUC1-
positive cells were mostly throughout all layers or predominantly in the lower layers, both 
of which included the invasive fronts.  This distribution pattern has been already noted by 
Baldus et al 15） and Hiraga et al 16）, who reported MUC1 expression as an independent factor 
indicative of unfavorable prognosis.  Moreover, we conrmed that the majority of tumors in 
the MUC1-H group exhibited high levels of continuous MUC1 expression in lymph node 
metastatic lesions, and that even in the MUC1-L group, 38% showed high levels of MUC1 
expression.
　This study also aimed to clarify the relationship between MUC1 expression and clinico-
pathological factors.  To date, MUC1 is known to be a signicant marker of unfavorable 
prognosis in colorectal cancer 4）.  In this study, we found that the MUC1 H-group exhibited 
a signicantly greater tumor size, greater number of ulcerated-type tumors, deeper inltra-
tion depth, lower states of differentiation, greater frequency of budding, and higher rate of 
lymph node metastasis than the MUC1 L-group.  These ndings indicate a strong correlation 
between MUC1 expression and malignant factors （Table 5）.  In an examination of only 
T3 cancer cases, although the number of cases was small and several factors lacked statisti-
cal signicance, the MUC1 H-group samples tended to show a stronger relationship with 
malignant factors than samples from the MUC1 L-group, as well as a signicant difference 
in lymph node metastases 17）（Table 5）.  Thus, these results indicate that MUC1 expression in 
colorectal cancer is related to malignancy 18）, affects localized progression of the cancer and 
its metastasis, and is useful as a tumor marker and treatment target 19，20）.
　Finally, MUC1 expression was found in various histological features of colorectal cancer, 
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making it impossible to identify specic morphological features of the tumor tissues that 
favor MUC1 expression.  However, the ndings of frequent MUC1 expression in the mono-
layer cuboidal （pancreatobiliary-type） neoplastic glands, which were often transformed from 
intestinal type glands, was considered important and a subject for future study.
Conclusion 
　In colorectal cancer, MUC1 expression increases with development of the tumor, and 
exhibits a strong correlation with malignant factors.  Thus, MUC1 is a useful malignant 
marker and an indicator for treatment regimen.  However, its expression is heterogeneous 
and localized ; therefore, it will be necessary to conrm the state of MUC1 expression with 
tissues including the invasive front or metastasis on a case-by-case basis.
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